• 1四川省樂山市市中區(qū)人民醫(yī)院心內(nèi)科,四川樂山 614000;2首都醫(yī)科大學附屬北京安貞醫(yī)院,北京 100029;

目的:觀察辛伐他汀、吡格列酮和苯磺酸左旋氨氯地平聯(lián)合治療代謝綜合征療效。方法:76例初診代謝綜合征患者,服用吡格列酮15mg/d、苯磺酸左旋氨氯地平25mg/d、辛伐他汀10mg/d,療程1個月。觀察治療前后血壓、腰圍、體重指數(shù)、血糖、血胰島素、血尿酸和血脂水平等變化。結(jié)果:患者治療后血糖、血脂、胰島素水平、血壓均明顯降低,差別有統(tǒng)計學意義(P lt;001)。腰圍、體重指數(shù)略有下降,無統(tǒng)計學意義,血尿酸變化不明顯。結(jié)論:吡格列酮、辛伐他汀和苯磺酸左旋氨氯地平聯(lián)合治療代謝綜合征能夠改善胰島素抵抗和代謝異常,療效可靠、服藥簡單、依從性好,效價比合理,無不良反應(yīng)。

引用本文： 尹黎波,李惠萍,郭敏霞,王春梅. 辛伐他汀、吡格列酮及苯磺酸左旋氨氯地平聯(lián)合治療代謝綜合征76例觀察. 華西醫(yī)學, 2009, 24(5): 1122-1124. doi: 復制

1. ALBERTI K G, ZIMMET P Z. Definition, diagnosis and classification of diabetes mellitus and its complications, part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J]. Diabet Med, 1998, 15(7): 539553.
2. BALKAU B, CHARLES M A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)[J]. Diabet Med, 1999,16(5): 442443.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report[J]. Circulation, 2002, 106 (25):31433421.
4. 金文勝,潘長玉.國際糖尿病聯(lián)盟關(guān)于代謝綜合證定義的全球共識[J].中華內(nèi)分泌代謝雜志, 2005, 21(4):412.
5. 田慧,潘長玉,陸菊明,等.老年男性人群2型糖尿病與代謝綜合征情況調(diào)查[J].中華老年多器官疾病雜志,2002,1(1):19.
6. 徐成斌.代謝綜合征[J]. 國外醫(yī)學 內(nèi)分泌學分冊,2005,25(1):36.
7. M ARIOLIS A, A LEVIZOS A, KOMPOTI M. Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes[J]. Cardiovasc Diabetol,2006, 5(1): 21.
8. HAN T S, WILLIAMS K, SATTAR N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study[J]. Obes Res,2002,10:923931[9]STEINBERGER J. Diagnosis of the metabolic syndrome in children[J]. Curr Opin Lipidol,2003,14:555559.
9. MAISON P, BYRNE C D, HALES C N, et al. Do different dimensions of the metabolic syndrome change together overtime? Evidence supporting obesity as the central feature[J]. Diabetes Care,2001,24:17581763.
10. HAFFNER S, TAEGT MEYER H. Epidemic obesity and the metabolic syndrome[J]. Circulation, 2003, 108(13):15411545.
11. LEBOVITZ H E. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus[J]. Am J Cardiol, 2002,90(5A):34 41.
12. PATRICIA I, TAKALA T, OIKONEN V, et al. Effect of during physiological hyperinsu linemia [J]. Diabetes Care, 2004, 27: 21722177.
13. KAIN K, CATTO A J, GRANT P J. Associations between insulin resistance and thrombotic risk factors in high risk South Asian subjects[J]. Diabet Med, 2003, 20:651655.
14. DAVIGNON J, MONTIGNY M, DUFOUR R. HMGCoA reductase inhibitors: a look back and a look ahead[J]. Can J Cardiol, 1992,8(8):843864.
15. ROSMOND R, CHAGNON Y C, HOLM G, et al. Hypertension in obesity and leptin receptor gene locus[J]. J Clin Endocrinol Metab,2000,85:31263131.
16. ARROWSMITH J E, CAMPBELL S F, CROSS P E, ABOTT RD, CELIS H, STAESSEN JA, et al. Longacting dihydropyruding calcium antagonista.1,2alkoxymethel derivatives incorporating basic substicents[J]. J Med Chem,1986,29(14):1 697701.
17. 胡大一,趙秀麗,孫寧玲,等.苯磺酸左旋胺氯地平與苯磺酸氨氯地平治療原發(fā)性輕中度高血壓的隨機、雙盲平行研究[J]. 中國醫(yī)刊, 2002,5(1):4751.
  1. 1. ALBERTI K G, ZIMMET P Z. Definition, diagnosis and classification of diabetes mellitus and its complications, part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J]. Diabet Med, 1998, 15(7): 539553.
  2. 2. BALKAU B, CHARLES M A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)[J]. Diabet Med, 1999,16(5): 442443.
  3. 3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report[J]. Circulation, 2002, 106 (25):31433421.
  4. 4. 金文勝,潘長玉.國際糖尿病聯(lián)盟關(guān)于代謝綜合證定義的全球共識[J].中華內(nèi)分泌代謝雜志, 2005, 21(4):412.
  5. 5. 田慧,潘長玉,陸菊明,等.老年男性人群2型糖尿病與代謝綜合征情況調(diào)查[J].中華老年多器官疾病雜志,2002,1(1):19.
  6. 6. 徐成斌.代謝綜合征[J]. 國外醫(yī)學 內(nèi)分泌學分冊,2005,25(1):36.
  7. 7. M ARIOLIS A, A LEVIZOS A, KOMPOTI M. Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes[J]. Cardiovasc Diabetol,2006, 5(1): 21.
  8. 8. HAN T S, WILLIAMS K, SATTAR N, et al. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study[J]. Obes Res,2002,10:923931[9]STEINBERGER J. Diagnosis of the metabolic syndrome in children[J]. Curr Opin Lipidol,2003,14:555559.
  9. 9. MAISON P, BYRNE C D, HALES C N, et al. Do different dimensions of the metabolic syndrome change together overtime? Evidence supporting obesity as the central feature[J]. Diabetes Care,2001,24:17581763.
  10. 10. HAFFNER S, TAEGT MEYER H. Epidemic obesity and the metabolic syndrome[J]. Circulation, 2003, 108(13):15411545.
  11. 11. LEBOVITZ H E. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus[J]. Am J Cardiol, 2002,90(5A):34 41.
  12. 12. PATRICIA I, TAKALA T, OIKONEN V, et al. Effect of during physiological hyperinsu linemia [J]. Diabetes Care, 2004, 27: 21722177.
  13. 13. KAIN K, CATTO A J, GRANT P J. Associations between insulin resistance and thrombotic risk factors in high risk South Asian subjects[J]. Diabet Med, 2003, 20:651655.
  14. 14. DAVIGNON J, MONTIGNY M, DUFOUR R. HMGCoA reductase inhibitors: a look back and a look ahead[J]. Can J Cardiol, 1992,8(8):843864.
  15. 15. ROSMOND R, CHAGNON Y C, HOLM G, et al. Hypertension in obesity and leptin receptor gene locus[J]. J Clin Endocrinol Metab,2000,85:31263131.
  16. 16. ARROWSMITH J E, CAMPBELL S F, CROSS P E, ABOTT RD, CELIS H, STAESSEN JA, et al. Longacting dihydropyruding calcium antagonista.1,2alkoxymethel derivatives incorporating basic substicents[J]. J Med Chem,1986,29(14):1 697701.
  17. 17. 胡大一,趙秀麗,孫寧玲,等.苯磺酸左旋胺氯地平與苯磺酸氨氯地平治療原發(fā)性輕中度高血壓的隨機、雙盲平行研究[J]. 中國醫(yī)刊, 2002,5(1):4751.